Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
Background:
Inflammatory bowel disease (IBD) is a term used to describe disorders that cause long-term inflammation in the digestive tract. Symptoms include stomach pain, diarrhea, and bleeding. Crohn's disease and ulcerative colitis are the 2 main types of IBD. Researchers want to conduct a natural history study to learn more about whether genetic factors can cause IBD; how immune cells contribute to IBD; and how diet, drugs, and disease affect those cells.
Objective:
To better understand IBD over time.
Eligibility:
Adults aged 18 to 85 years with Crohn's disease, ulcerative colitis, or another IBD. Their healthy relatives are also needed.
Design:
Affected participants will have clinic visits every 6 months for 3 years.
Once a year, they will have these procedures:
A physical exam with blood and stool samples.
Ultrasound of the abdomen. A wand will be rolled over the skin. It uses sound waves to capture images of the intestines.
Magnetic resonance imaging (MRI) scan. They will lie on a table that slides into a tube. Magnetic fields will capture images of the intestines.
Colonoscopy. A long, flexible tube with a video camera will be inserted into the rectum to view the entire colon. Up to 12 tissue samples may be taken.
Upper endoscopy, for those with Crohn's disease. A long, thin tube with a camera will be inserted through the mouth and into the first part of the small intestine. Up to 12 small tissue samples may be taken.
Questionnaires. Participants will answer questions about their disease and their diet.
Midyear visits will include a physical exam, blood and stool collection, ultrasound, and questionnaires
Healthy relatives will have 1 blood draw for genetic tests.
Aperçu de l'étude
Statut
Description détaillée
Study Description:
This is a single-site, hypothesis-generating natural history study aiming to follow participants with inflammatory bowel disease. Participants will be followed long-term with a focus on immunophenotyping their conditions. Adult family members of participants will also be invited to enroll to provide blood samples for immune and genetic analyses.
Objectives:
Primary Objective: To collect longitudinal clinical data and specimens, with the goal of identifying novel biomarkers correlating with disease activity or response to therapy
Secondary Objectives:
- To identify the dynamic molecular and immunological changes associated with chronic GI inflammation and mechanisms of response to FDA approved (biologic and small molecule inhibitors) therapies for IBD
- To study the molecular genetics underlying chronic GI inflammation
- To longitudinally quantify and characterize the nutritional status, food components, and overall diet of patients with IBD
Endpoints:
Primary Endpoint:
1. Longitudinal collection of clinical data, biospecimens, and disease assessments at 6-month intervals over at least 3 years
Secondary Endpoints:
1.A) Mean change over baseline of immune cell populations, cellular transcript and protein expression, and cytokine levels in peripheral blood and mucosal tissue across at least 3 study visits during a two-year period.
1.B) Assessment of disease activity (endoscopic evaluation, and histopathology) at each endoscopy and evaluation of progression of disease activity across at least 3 endoscopies during a two-year period. If a treatment is implemented, then disease activity will be assessed and compared over consecutive endoscopies.
- C) Identification of molecular patterns or immune signatures that correlate with disease activity and response to treatment
- A) Quantification of gene expression data and its trajectory over the course of disease and after therapy
2.B) Establishment of positive or negative correlation between candidate susceptible genes and disease phenotype
3.A) To establish positive or negative correlations between specific food components and nutrient amounts with disease activity obtained from questionnaires over 12 months
3.B) to establish correlations with nutritional data and the microbiome over 12 months
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Kristi C Briggs, M.D.
- Numéro de téléphone: (301) 480-2785
- E-mail: kristi.briggs@nih.gov
Lieux d'étude
-
-
Maryland
-
Bethesda, Maryland, États-Unis, 20892
- Recrutement
- National Institutes of Health Clinical Center
-
Contact:
- NIH Clinical Center Office of Patient Recruitment (OPR)
- Numéro de téléphone: TTY dial 711 800-411-1222
- E-mail: ccopr@nih.gov
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Patients with known or suspected inflammatory bowl disease
La description
- INCLUSION CRITERIA
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
Affected Participant cohort:
-
Adults 18 - 85 years of age
-
History of:
- a verifiable diagnosis of Crohn's disease, ulcerative colitis, or IBD known to be associated with a co-existing condition (such as CTLA4 deficiency or common variable immune deficiency) and which is supported by characteristic clinical features, radiographic or endoscopic findings, or consistent histopathologic mucosal changes related to chronic inflammation; and/or
- a defined genetic syndrome/mutation linked to inflammatory bowel disease risk with or without symptoms or findings consistent with IBD
-
Presence of a referring community physician who would be able to manage care outside of NIH
Unaffected family member of participant: immediate relative to the enrolled participant (mother, father, sibling, or adult child) may be recruited and enrolled to improve interpretation of genetic results or expand the phenotype of the IBD
- Adults 18 - 99 years of age
- In good general health
- No medical diagnosis of IBD
EXCLUSION CRITERIA
An individual who meets any of the following criteria will be excluded from participation in this study:
- Unable or unwilling to provide informed consent
- Evidence of significant medical illnesses that the investigators feel may interfere with study evaluations and procedures
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
|---|
|
Affected participants
participants affected with inflammatory bowel disease |
|
Unaffected family members
unaffected family member of participant |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
To collect longitudinal clinical data and specimens, with the goal of identifying novel biomarkers correlating with disease activity or response to therapy
Délai: 3 years
|
3 years
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chercheur principal: Kristi C Briggs, M.D., National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 10002555
- 002555-DK
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .